PDL BioPharma Reports Q3 EPS Above View, Revenue Below Street View
By Benzinga Staff
October 28, 2009 6:54 AM
October 28, 2009 6:54 AM
PDL BioPharma reports Q3 EPS 29c vs street view of 26c. PDL BioPharma (Nasdaq: PDLI) reports Q3 revenue $71.4M vs consensus of $76.48M.
PDL BioPharma lowers FY09 revenue guidance to $310M to $320M. PDL previously had seen FY09 revenue of $319M to $325M versus the street view of $331.96M.
(c) 2011 Benzinga.com. All rights reserved. This material may not be published in its entirety or redistributed without the approval of Benzinga.
We're Loving
